Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 73, Issue 6, 2005, Pages 411-417

  Pommery, J ^a   Pommery, N ^a   Henichart J P ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYHEPTADECATRIENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYOCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CALCIMYCIN; CELECOXIB; CYCLOOXYGENASE 2; ICOSANOID; INDOMETACIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONCENTRATION RESPONSE; DATA ANALYSIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; ICOSANOID METABOLISM; PRIORITY JOURNAL;

ARACHIDONIC ACID; CALCIMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; HUMANS; HYDROXYUREA; INDOMETHACIN; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; LIPOXYGENASE INHIBITORS; PYRAZOLES; SULFONAMIDES;

EID: 27644592518     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2005.08.009     Document Type: Article

References (23)

1. A.G. Spencer, J.W. Woods, T. Arakawa, I.I. Singer, and W.L. Smith Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy J. Biol. Chem. 273 1998 9886 9893
2. M. Peters-Golden, and T.G. Brock Intracellular compartmentalization of leukotriene biosynthesis Am. J. Respir. Crit. Care Med. 161 2000 S36 S40
3. S. Narumiya, and G.A. FitzGerald Genetic and pharmacological analysis of prostanoid receptor function J. Clin. Invest. 108 2001 25 30
4. K. Yu, W. Bayona, C.B. Kallen, H.P. Harding, C.P. Ravera, G. McMahon, M. Brown, and M.A. Lazar Differential activation of peroxisome proliferator- activated receptors by eicosanoids J. Biol. Chem. 270 1995 23975 23983
5. N. Li, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C.S. Yang, and X. Chen Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib Clin. Cancer Res. 11 2005 2089 2096
6. M. Romano, and J. Claria Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy FASEB J. 17 2003 1986 1995
7. D. Nie, and K.V. Honn Eicosanoid regulation of angiogenesis in tumors Semin. Thromb. Hemost. 30 2004 119 125
8. M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. DuBois Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716
9. P.A. Bunn Jr., and R.L. Keith The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer Clin. Lung Cancer 3 2002 271 277
10. H. Fujita, K. Koshida, E.T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, and A. Mizokami Cyclooxygenase-2 promotes prostate cancer progression Prostate 53 2002 232 240
11. S. Fiorucci, M. Meli, M. Bucci, and G. Cirino Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 62 2001 1433 1438
12. C. Charlier, and C. Michaux Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs Eur. J. Med. Chem. 38 2003 645 659
13. S. Barbey, L. Goossens, T. Taverne, J. Cornet, V. Choesmel, C. Rouaud, G. Gimeno, S. Yannic-Arnoult, C. Michaux, C. Charlier, R. Houssin, and J.P. Hénichart Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor Bioorg. Med. Chem. Lett. 12 2002 779 782
14. N. Pommery, T. Taverne, A. Telliez, L. Goossens, C. Charlier, J. Pommery, J.F. Goossens, R. Houssin, F. Durant, and J.P. Hénichart New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy J. Med. Chem. 47 2004 6195 6206
15. H. Krum, D. Liew, J. Aw, and S. Haas Cardiovascular effects of selective cyclooxygenase-2 inhibitors Expert. Rev. Cardiovasc. Ther. 2 2004 265 270
16. I. Shureiqi, and S.M. Lippman Lipoxygenase modulation to reverse carcinogenesis Cancer Res. 61 2001 6307 6312
17. U. Kelavkar, W. Glasgow, and T.E. Eling The effect of 15-lipoxygenase-1 expression on cancer cells Curr. Urol. Rep. 3 2002 207 214
18. P. Borgeat, S. Picard, P. Vallerand, S. Bourgoin, A. Odeimat, P. Sirois, and P.E. Poubelle Automated on-line extraction and profiling of lipoxygenase products of arachidonic acid by high-performance liquid chromatography Methods Enzymol. 187 1990 98 116
19. M.E. Surette, A. Odeimat, R. Palmantier, S. Marleau, P.E. Poubelle, and P. Borgeat Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo Anal. Biochem. 216 1994 392 400
20. T.J. Carty, F.J. Sweeney, R.J. Griffiths, J.D. Eskra, M.J. Ernest, J.S. Pillar, J.D. Cheng, L.D. Loose, P.A. Joseph, P.P. Pazoles, P.F. Moore, A. Nagahisa, S. Murase, and S.B. Kadin Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models Inflamm. Res. 46 1997 168 179
21. K.A. Berry, P. Borgeat, J. Gosselin, L. Flamand, and R.C. Murphy Urinary metabolites of leukotriene B4 in the human subject J. Biol. Chem. 278 2003 24449 24460
22. L.C. Hsi, L.C. Wilson, and T.E. Eling Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma J. Biol. Chem 277 2002 40549 40556
23. H. Pham, T. Banerjee, and V.A. Ziboh Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells Int. J. Cancer 111 2004 192 197